Initiator Pharma A/S Share Price

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 08:59:59 26/04/2024 pm IST 5-day change 1st Jan Change
8.78 SEK -1.79% Intraday chart for Initiator Pharma A/S -2.23% -4.98%

Financials

Sales 2023 - Sales 2024 * 161M 23.09M 252M 1.93B Capitalization 296M 42.44M 464M 3.54B
Net income 2023 -22M -3.15M -34.47M -263M Net income 2024 * 103M 14.77M 161M 1.23B EV / Sales 2023 -
Net cash position 2023 24.34M 3.49M 38.13M 291M Net cash position 2024 * 60M 8.6M 94.01M 717M EV / Sales 2024 * 1.47 x
P/E ratio 2023
-14.1 x
P/E ratio 2024 *
3.11 x
Employees 3
Yield 2023 *
-
Yield 2024 *
-
Free-Float 82.68%
More Fundamentals * Assessed data
Dynamic Chart
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Initiator Pharma Issues New Shares for Debt Conversion MT
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine CI
Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction CI
Initiator Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Initiator Pharma Wins EU Patent for Erectile Dysfunction, Depression Drug Candidate MT
Initiator Pharma A/S Obtains IP 2018 Patent in Europe for Treatment of Erectile Dysfunction and Depression CI
Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial CI
Initiator Pharma A/S (OM:INIT) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on May 26, 2023. CI
Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine CI
Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction CI
Initiator Pharma A/S's Equity Buyback announced on July 25, 2022 has expired. CI
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
1 day-1.79%
1 week-2.23%
Current month-3.52%
1 month-1.79%
3 months+4.03%
6 months-3.94%
Current year-4.98%
More quotes
1 week
8.50
Extreme 8.5
9.12
1 month
8.32
Extreme 8.32
9.48
Current year
7.50
Extreme 7.5
9.50
1 year
5.00
Extreme 5
12.20
3 years
4.02
Extreme 4.02
12.20
5 years
3.93
Extreme 3.93
12.20
10 years
2.62
Extreme 2.62
12.20
More quotes
Managers TitleAgeSince
Founder 61 01/16/01
Founder 50 01/16/01
Founder 56 01/16/01
Members of the board TitleAgeSince
Director/Board Member 66 01/16/01
Chairman 64 01/16/01
Director/Board Member 66 01/22/01
More insiders
Date Price Change Volume
26/24/26 8.78 -1.79% 50,199
25/24/25 8.94 0.00% 7,660
24/24/24 8.94 -0.67% 12,202
23/24/23 9 +2.97% 23,425
22/24/22 8.74 -2.67% 6,062

Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:59 pm IST

More quotes
Initiator Pharma A/S is a Denmark-based company engaged in the biotechnology sector. The Company focuses on developing drugs for treatment of erectile dysfunction.
More about the company

Annual profits - Rate of surprise